Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
出版年份 2020 全文链接
标题
Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
作者
关键词
-
出版物
Journal of Clinical Medicine
Volume 9, Issue 4, Pages 1047
出版商
MDPI AG
发表日期
2020-04-08
DOI
10.3390/jcm9041047
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases
- (2019) Anna-Lena Volckmar et al. INTERNATIONAL JOURNAL OF CANCER
- Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11
- (2019) Linnéa La Fleur et al. LUNG CANCER
- Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
- (2019) Minjiang Chen et al. EBioMedicine
- Prognostic value of KRAS/TP53/PIK3CA in non‑small cell lung cancer
- (2019) Jiayi Zhao et al. Oncology Letters
- Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer
- (2019) Yutao Liu et al. Oncology Letters
- Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
- (2019) Helei Hou et al. Cancer Management and Research
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
- (2019) Alessandro Leonetti et al. BRITISH JOURNAL OF CANCER
- The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base
- (2018) Xiao-Dong Jiao et al. LUNG CANCER
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas
- (2018) Ying Jin et al. LUNG CANCER
- Short-Term Responders of Non–Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms
- (2018) Yanjun Xu et al. Translational Oncology
- Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
- (2018) Youjin Kim et al. Journal of Thoracic Oncology
- Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes
- (2017) Paul A. VanderLaan et al. LUNG CANCER
- Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)
- (2017) Catherine Labbé et al. LUNG CANCER
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
- (2016) Matteo Canale et al. CLINICAL CANCER RESEARCH
- Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study
- (2016) Jianxin Shi et al. PLOS MEDICINE
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non-Small Cell Lung Cancer
- (2014) M. A. Molina-Vila et al. CLINICAL CANCER RESEARCH
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- p53 mutations in cancer
- (2012) Patricia A. J. Muller et al. NATURE CELL BIOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search